# CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma

> **NCT06617286** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **New York Medical College** · enrollment: 21 (estimated)

## Conditions studied

- Classical Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** CD30 CAR T-cell

## Key facts

- **NCT ID:** NCT06617286
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2039-12-31
- **Final completion:** 2040-12-31
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06617286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06617286, "CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06617286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*